QQ客服 官方微博 反馈留言

浏览/检索结果: 共7条，第1-7条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Neoadjuvant immunotherapy in non-small-cell lung cancer: a narrative review on mechanisms, efficacy and safety 期刊论文 JOURNAL OF THORACIC DISEASE, 2022 作者:  Shao, Lan;  Lou, Guangyuan 收藏  |  浏览/下载：18/0  |  提交时间：2022/12/22 Neoadjuvant  immunotherapy  immune-checkpoint inhibitors  non-small cell lung cancer (NSCLC)   Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial 期刊论文 LANCET ONCOLOGY, 2022, 卷号: 23 作者:  Zhou, Qing;  Chen, Ming;  Jiang, Ou;  Pan, Yi;  Hu, Desheng 收藏  |  浏览/下载：104/0  |  提交时间：2022/03/21 ORIENTAL: An open label, multicenter, phase IIIb study of first-line durvalumab plus platinum-based chemotherapy in Chinese patients with extensive stage small cell lung cancer (ES-SCLC) 期刊论文 JOURNAL OF THORACIC ONCOLOGY, 2021, 卷号: 16 作者:  Cheng, Y.;  Wang, J.;  Cang, S.;  Cao, L.;  Chen, E. 收藏  |  浏览/下载：57/0  |  提交时间：2021/04/26 Cost-effectiveness analysis of durvalumab plus etoposide: platinum in the first-line therapy of extensive stage small-cell lung cancer from the Chinese payers' perspective 期刊论文 TUMORI JOURNAL, 2021 作者:  Tong, Ying-hui;  Ding, Hai-ying;  Xin, Wen-xiu;  Zhong, Li-ke;  Xu, Gao-qi 收藏  |  浏览/下载：38/0  |  提交时间：2021/08/30 Cost-effectiveness  durvalumab  etoposide plus platinum chemotherapy  first-line treatment  SCLC   Durvalumab monotherapy as a third-line treatment for extensive-stage small-cell lung cancer: a case report 期刊论文 ANNALS OF PALLIATIVE MEDICINE, 2020, 卷号: 9 作者:  Zhou, Qinfei;  Zhao, Jiazheng;  Wang, Jie;  Bao, Guanai;  Gong, Li-Yan 收藏  |  浏览/下载：24/0  |  提交时间：2020/11/26 Small-cell lung cancer (SCLC)  immunotherapy  durvalumab  third-line treatment  case report   A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after curative hepatic resection or ablation: EMERALD-2 会议论文 作者:  Knox, J.;  Cheng, A.;  Cleary, S.;  Galle, P.;  Kokudo, N. 收藏  |  浏览/下载：8/0  |  提交时间：2019/12/05 Durvalumab治疗放化疗后不可切除的局部晚期非小细胞肺癌的III期试验-PACFIC研究解读 期刊论文 2019, 卷号: 29, 期号: 3, 页码: 233-240 作者:  郭兰伟;  王慧娟 收藏  |  浏览/下载：3/0  |  提交时间：2020/01/03 Durvalumab治疗  不可切除  局部晚期非小细胞肺癌